<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nedosiran: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nedosiran: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nedosiran: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="142919" href="/d/html/142919.html" rel="external">see "Nedosiran: Drug information"</a> and <a class="drug drug_patient" data-topicid="142982" href="/d/html/142982.html" rel="external">see "Nedosiran: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F59039987"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Rivfloza</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F58701144"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Lactate Dehydrogenase A (LDHA)-Directed Small Interfering Ribonucleic Acid (siRNA)</span></li></ul></div>
<div class="block dop drugH1Div" id="F58733115"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d611b7b1-21ef-4683-8869-1e300c0b0f03">Primary hyperoxaluria type 1</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary hyperoxaluria type 1: Note:</b> Dose based on actual body weight.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥9 to &lt;12 years:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;50 kg: SUBQ: 3.3 mg/kg once monthly; round dose to nearest 0.1 mL; maximum dose: 128 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">≥50 kg: SUBQ: 160 mg once monthly.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;50 kg: SUBQ: 128 mg once monthly.</p>
<p style="text-indent:-2em;margin-left:6em;">≥50 kg: SUBQ: 160 mg once monthly.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F58733116"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered Kidney Function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥9 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F58733117"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥9 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (ie, <i>total bilirubin = ULN and AST &gt; ULN</i>
<b>or </b>
<i>total bilirubin &gt;1 to 1.5 × ULN and any AST</i>): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate to severe impairment (ie, <i>total bilirubin &gt;1.5 × ULN with any AST</i>): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F58728336"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="142919" href="/d/html/142919.html" rel="external">see "Nedosiran: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d611b7b1-21ef-4683-8869-1e300c0b0f03">Primary hyperoxaluria type 1</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary hyperoxaluria type 1: Note:</b> Dose based on actual body weight.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>&lt;50 kg: </i>
<b>SUBQ:</b> 128 mg once monthly.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>≥50 kg</i>: <b>SUBQ:</b> 160 mg once monthly.</p></div>
</div>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed dose:</i> If dose missed, administer as soon as possible. If the dose is missed by &gt;7 days, administer as soon as possible and resume monthly dosing schedule based on most recently administered dose.</p></div>
<div class="block dora drugH1Div" id="F58728338"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer’s labeling; nedosiran pharmacokinetics may be altered in patients with impaired kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37605486']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37605486'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37605486']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37605486'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F58728339"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Child-Turcotte-Pugh A:</b> No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Child-Turcotte-Pugh B and C:</b> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F58754153"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in children, adolescents, and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Local: Injection-site reaction (including bruising at injection site, erythema at injection site, pain at injection site, rash at injection site)</p></div>
<div class="block coi drugH1Div" id="F58700949"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F58728291"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Injection-site reactions: Injection-site reactions, including erythema, pain, bruising, and rash, may occur; most reactions are mild in intensity.</p></div>
<div class="block prod-avail drugH1Div" id="F58700943"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Rivfloza: FDA approved October 2023; availability anticipated in 2024.</p></div>
<div class="block foc drugH1Div" id="F59039988"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous, as sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rivfloza: 80 mg/0.5 mL (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous, as sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rivfloza: 128 mg/0.8 mL (0.8 mL); 160 mg/mL (1 mL)</p></div>
<div class="block geq drugH1Div" id="F59039986"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block admp drugH1Div" id="F58733133"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">SUBQ: If refrigerated, allow syringe or vial to warm to room temperature for 30 minutes prior to use. Administer SUBQ into the abdomen (avoiding the 2-inch area around the navel) or upper thigh. Inject at a 45° angle into pinched skin. Do not inject into veins or areas where the skin is scarred or bruised. Solution should be colorless to yellow and particle free; do not use if cloudy or contains particulate matter. Gently and slowly push plunger rod as far as it will go to inject the full dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prefilled syringe:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥9 to &lt;12 years and weight ≥50 kg: Dose should be administered by health care professional or trained caregiver.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: Dose may be administered by health care professional, trained caregiver, or patient.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Vial:</i> 80 mg/0.5 mL: <b>Note: </b>Round dose to nearest 0.1 mL. Intended for single use only; does not contain a preservative; discard unused portion. If you see large bubbles, tap the side of the syringe to move the bubbles to the top and gently push air back into vial. Ensure appropriate dose is in syringe after clearing bubbles.</p>
<p style="text-indent:-2em;margin-left:6em;">Dose ≤0.5 mL: Withdraw appropriate dose into one syringe.</p>
<p style="text-indent:-2em;margin-left:6em;">Dose ≥0.6 mL: Withdraw appropriate dose into two syringes (maximum volume = 0.5 mL/syringe) and administer into two different locations (eg, if injecting into abdomen, inject into two different areas of abdomen).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed dose:</i> If dose missed, administer as soon as possible. If the dose is missed by &gt;7 days, administer as soon as possible and resume monthly dosing schedule based on the most recently administered dose.</p></div>
<div class="block adm drugH1Div" id="F58728340"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>SUBQ:</b> Administer by a health care professional, caregiver, or patient if ≥12 years of age. If refrigerated, allow syringe to warm to room temperature for 30 minutes prior to use. May inject into the abdomen (avoiding the 2-inch area around the navel) or upper thigh. Do not inject into veins or areas where the skin is scarred or bruised. Clean planned injection site and uncap needle. Inject at a 45° angle into pinched skin. Push plunger rod as far as it will go to inject the full dose.</p></div>
<div class="block sts drugH1Div" id="F58728293"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials and prefilled syringes between 2°C to 8°C (36°F to 46°F). Can be stored, if needed, at 15°C to 30°C (59°F to 86°F) for a maximum of 28 days (4 weeks). Do not freeze. Store in original carton, away from direct heat and light.</p></div>
<div class="block usep drugH1Div" id="F58701148"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">To lower urinary oxalate levels in patients with primary hyperoxaluria type 1 and relatively preserved kidney function (eg, eGFR ≥30 mL/minute/1.73 m<sup>2</sup>) (FDA approved in ages ≥9 years and adults).</p></div>
<div class="block cyt drugH1Div" id="F58739437"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F58739434"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F58728289"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were not observed in animal reproduction studies except with dosing that also caused maternal toxicity.</p></div>
<div class="block mopp drugH1Div" id="F58733134"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Kidney function, heart rate (tachycardia/tachyarrhythmia), signs and symptoms of urinary stone formation, injection-site reactions (Baum 2023).</p></div>
<div class="block pha drugH1Div" id="F58728294"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Nedosiran is a double-stranded siRNA, conjugated to GalNAc aminosugar residues that bind to asialoglycoprotein receptors allowing delivery to hepatocytes. Nedosiran interrupts intracellular messenger ribonucleic acids (mRNAs), thereby interrupting formation of hepatic lactate dehydrogenase, which reduces the production of oxalate by the liver.</p></div>
<div class="block phk drugH1Div" id="F58728326"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> At the recommended doses, pharmacokinetic exposure of nedosiran in pediatric patients ≥9 years is similar to adult patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Onset: 30 days after first SUBQ dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: No accumulation in the plasma after repeated monthly dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 126 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 85.6%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: By endo- and exonucleases to shorter oligonucleotides.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 15 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Median: 6 hours; range: 2 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine: ~27% as unchanged drug.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37605486">
<a name="37605486"></a>Amrite A, Fuentes E, Marbury TC, Zhang S. Safety, pharmacokinetics, and exposure-response modeling of nedosiran in participants with severe chronic kidney disease. <i>Clin Pharmacol Drug Dev</i>. Published online August 21, 2023. doi:10.1002/cpdd.1320<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nedosiran-pediatric-drug-information/abstract-text/37605486/pubmed" id="37605486" target="_blank">37605486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36007597">
<a name="36007597"></a>Baum MA, Langman C, Cochat P, et al; PHYOX2 study investigators. PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. <i>Kidney Int.</i> 2023;103(1):207-217. doi:10.1016/j.kint.2022.07.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nedosiran-pediatric-drug-information/abstract-text/36007597/pubmed" id="36007597" target="_blank">36007597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rivfloza.1">
<a name="Rivfloza.1"></a>Rivfloza (nedosiran) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rivfloza.1">
<a name="Rivfloza.1"></a>Rivfloza (nedosiran) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; October 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 142974 Version 9.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
